CHONDROGRID: A PILOT CLINICAL STUDY

The intra-articular administration of hydrolyzed collagen as a possible arthrosis treatment addressing both function and symptoms. 

The sheet summarizes a retrospective pilot study concerning the clinical data of 20 patients affected by knee arthrosis, treated with CHondroGrid (Bioteck), a device indicated for the treatment of painful symptoms and loss of functionality in the main joints. The medical records included the AP weight-bearing X-rays of the joint before treatment (baseline), and the Lequesne index, the WOMAC score, the subjective VAS score measured both at rest and in motion at the baseline, following each injection and 6 months after the third injection (follow-up). Following treatment, all the parameters covered by the study significantly decreased as of the very first injection; they further decreased following the second injection and then remained unchanged over time. The study did not find any side effects associated with the use of the device. 

PRODUCTS USED: CHondroGrid CHG-004 CHG-PK4